Cooley Advised Prana Therapies on Agreement to Be Acquired By Bolt Biotherapeutics
Cooley advised Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies, on its agreement to be acquired by Bolt Biotherapeutics, a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies. Following the acquisition, the Company will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned. The acquisition was structured as a sign-and-close reverse merger, in which the parties entered into a merger agreement for a stock-for-stock transaction.
The transaction was announced publicly in this press release.
Ken Rollins, Rama Padmanabhan, Madison Jones, Jenny Ge, Rajdeep Bains, and Caroline Diemer led the team advising Prana Therapies.
Charity Williams, Alessandra Murata, Ross Eberly, Alexander Lee, Megan Browdie, Stella Sarma, Wade Andrews, Brittany Wightman, Leah Duncan, Camille Awono, Michael Kelker, Lexi Arnold, Jessica Kocinski, Sharon Connaughton, Longbo Wang, Carly Robinson, Joe Perry, Mark Cornillez-Ty, Benjamin Sweeney, Christopher Kimball, Annie Froehlich, Karen Tsai, Natasha Leskovsek, Phil Mitchell, Jennifer Shanley, Sarah Miller, Andrew Epstein, Mari Dugas, Calvin Lee, Jacob Lahana, Kathryn Sorenson, Tal Simon, and Breanna Qin provided invaluable support.
Cooley previously advised Prana Therapies on its Series A Financing in 2026.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.